Dana-Farber Cancer Institute | Strategic Alliance Partners

Wenxin (Vincent) Xu, MD, discusses ongoing efforts to identify new biomarkers in metastatic renal cell carcinoma.

Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute.

Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

Dr Wagner discusses unmet needs for patients with PEComa, ongoing research to address these gaps, and findings from the AMPECT trial.

Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.

Wenxin (Vincent) Xu, MD, highlights research in renal cell carcinoma, spotlighting developments and updates in patients with non-clear cell disease.

Jennifer R. Brown, MD, PhD, discusses results from a genomic analysis of responses with pirtobrutinib in patients with chronic lymphocytic leukemia.

Mary-Ellen Taplin, MD, discusses ways to mitigate health care disparities in the treatment of patients with prostate cancer.

Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.

Anthony V. D'Amico, MD, PhD, on the advancements in high-risk prostate cancer diagnosis and management

In the GENERATE study, 90% of those who viewed an online genetic education program chose to be tested for inherited predisposition to pancreatic cancer.

Drs Cutler and Safah look to the future of chronic GvHD treatment and discuss ongoing research, highlighting studies investigating axatilimab and abatacept.

Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.

Mary-Ellen Taplin, MD, discusses strategies to mitigate health care inequities in prostate cancer.

The Third Transatlantic Exchange in Oncology Conference will focus on liquid biopsy as an emerging approach in precision cancer medicine.

Grant winner Tyler Miller, MD, PhD, outlines innovative plans for glioma research.

Drs Safah and Cutler discuss treatment practices for patients with steroid-refractory graft-vs-host disease and highlight patients who are steroid dependent.

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome.

Ko Un “Clara” Park, MD, discusses the FDA's vote in support of Lumisight for patients with breast cancer undergoing breast conserving surgery.

Hana Safah, MD, reviews the NIH staging system for graft-vs-host disease and discusses the importance of staging in determining prognosis and informing treatment decisions.

Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.

Different immunomodulatory mechanisms are at work depending on the type of treatment and the genetic makeup of the cancer in RCC.

The panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.

The expert doctors discuss the impact of chronic GVHD on long-term survivors' quality of life (QoL). The panel explores the significance of patient-reported outcomes (PROs), challenges in their implementation, and the evolving role of PROs in assessing and improving QoL in chronic GVHD patients.

Hematologist-oncologists Corey Cutler, MD, MPH, and Hana Safah, MD, discuss how graft-vs-host disease presents and the importance of early intervention.

Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.

Pasi A. Jänne, MD, PhD discusses the FDA approval of osimertinib plus chemotherapy for patients with EGFR-positive non–small cell lung cancer.

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.